Search

Your search keyword '"BARLESI, Fabrice"' showing total 1,545 results
Start Over Author "BARLESI, Fabrice"
1,545 results on '"BARLESI, Fabrice"'

2. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

Author

Vasseur, Damien, Bigot, Ludovic, Beshiri, Kristi, Flórez-Arango, Juan, Facchinetti, Francesco, Hollebecque, Antoine, Tselikas, Lambros, Aldea, Mihaela, Blanc-Durand, Felix, Gazzah, Anas, Planchard, David, Lacroix, Ludovic, Pata-Merci, Noémie, Nobre, Catline, Da Silva, Alice, Nicotra, Claudio, Ngo-Camus, Maud, Braye, Floriane, Nikolaev, Sergey I., Michiels, Stefan, Jules-Clement, Gérôme, Olaussen, Ken André, André, Fabrice, Scoazec, Jean-Yves, Barlesi, Fabrice, Ponce, Santiago, Soria, Jean-Charles, Besse, Benjamin, Loriot, Yohann, and Friboulet, Luc

Published
2024
Full Text
View/download PDF

3. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.

Author

Negrao, Marcelo, Araujo, Haniel, Lamberti, Giuseppe, Cooper, Alissa, Akhave, Neal, Zhou, Teng, Delasos, Lukas, Hicks, J, Aldea, Mihaela, Minuti, Gabriele, Hines, Jacobi, Aredo, Jacqueline, Dennis, Michael, Scott, Susan, Bironzo, Paolo, Scheffler, Matthias, Christopoulos, Petros, Stenzinger, Albrecht, Riess, Jonathan, Kim, So, Goldberg, Sarah, Li, Mingjia, Wang, Qi, Qing, Yun, Ni, Ying, Do, Minh, Lee, Richard, Ricciuti, Biagio, Alessi, Joao, Wang, Jing, Resuli, Blerina, Landi, Lorenza, Tseng, Shu-Chi, Nishino, Mizuki, Digumarthy, Subba, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Vaporciyan, Ara, Blumenschein, George, Zhang, Jianjun, Owen, Dwight, Mountzios, Giannis, Shu, Catherine, Bestvina, Christine, Garassino, Marina, Marrone, Kristen, Gray, Jhanelle, Patel, Sandip, Cummings, Amy, Wakelee, Heather, Wolf, Juergen, Scagliotti, Giorgio, Cappuzzo, Federico, Barlesi, Fabrice, Patil, Pradnya, Drusbosky, Leylah, Gibbons, Don, Meric-Bernstam, Funda, Lee, J, Heymach, John, Hong, David, Heist, Rebecca, Awad, Mark, Skoulidis, Ferdinandos, Blakely, Collin, and Chakrabarti, Turja

Subjects
Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Kelch-Like ECH-Associated Protein 1, Phosphatidylinositol 3-Kinases, Mutation, NF-E2-Related Factor 2, DNA Helicases, Nuclear Proteins, Transcription Factors
Abstract

UNLABELLED: Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis of 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations in KEAP1, SMARCA4, and CDKN2A as major independent determinants of inferior clinical outcomes with KRASG12Ci monotherapy. Collectively, comutations in these three tumor suppressor genes segregated patients into distinct prognostic subgroups and captured ∼50% of those with early disease progression (progression-free survival ≤3 months) with KRASG12Ci. Pathway-level integration of less prevalent coalterations in functionally related genes nominated PI3K/AKT/MTOR pathway and additional baseline RAS gene alterations, including amplifications, as candidate drivers of inferior outcomes with KRASG12Ci, and revealed a possible association between defective DNA damage response/repair and improved KRASG12Ci efficacy. Our findings propose a framework for patient stratification and clinical outcome prediction in KRASG12C-mutant NSCLC that can inform rational selection and appropriate tailoring of emerging combination therapies. SIGNIFICANCE: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose a framework for patient stratification and treatment personalization based on the comutational status of individual tumors. See related commentary by Heng et al., p. 1513. This article is highlighted in the In This Issue feature, p. 1501.

Published
2023

5. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Author

Felip, Enriqueta, Metro, Giulio, Soo, Ross A., Wolf, Jürgen, Solomon, Benjamin J., Tan, Daniel SW, Ardizzoni, Andrea, Lee, Dae Ho, Sequist, Lecia V., Barlesi, Fabrice, Ponce-Aix, Santiago, Abreu, Delvys Rodriguez, Campelo, Maria Rosario Garcia, Sprauten, Mette, Djentuh, Leslie O’Sullivan, Smith, Nathalie, Jary, Aline, Belli, Riccardo, Glaser, Sabine, Zou, Mike, Cui, Xiaoming, Giovannini, Monica, and Yang, James Chih-Hsin

Published
2024
Full Text
View/download PDF

7. Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience

Author

Parisi, Claudia, Benitez, José Carlos, Lecourt, Hélène, dall’Olio, Filippo Gustavo, Aldea, Mihaela, Blanc-Durand, Felix, Vergé, Véronique, Quivoron, Cyril, Naltet, Charles, Abdayem, Pamela, Lavaud, Pernelle, Ghigna, Maria Rosa, Friboulet, Luc, Loriot, Yohann, De Botton, Stéphane, Ribrag, Vincent, Ardizzoni, Andrea, Planchard, David, Soria, Jean-Charles, Barlesi, Fabrice, and Besse, Benjamin

Published
2024
Full Text
View/download PDF

8. Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study

Author

Rousseau, Adrien, Michiels, Stefan, Simon-Tillaux, Noémie, Lolivier, Alexandre, Bonastre, Julia, Planchard, David, Barlesi, Fabrice, Remon, Jordi, Lavaud, Pernelle, Aldea, Mihaela, Frelaut, Maxime, Le Pechoux, Cecile, Botticella, Angela, Levy, Antonin, Gazzah, Anas, Foulon, Stephanie, and Besse, Benjamin

Published
2024
Full Text
View/download PDF

9. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review

Author

Géraud, Arthur, Hueso, Thomas, Laparra, Ariane, Bige, Naike, Ouali, Kaissa, Cauquil, Cécile, Stoclin, Annabelle, Danlos, François-Xavier, Hollebecque, Antoine, Ribrag, Vincent, Gazzah, Anas, Goldschmidt, Vincent, Baldini, Capucine, Suzzoni, Steve, Bahleda, Rastislav, Besse, Benjamin, Barlesi, Fabrice, Lambotte, Olivier, Massard, Christophe, Marabelle, Aurélien, Castilla-Llorente, Cristina, Champiat, Stéphane, and Michot, Jean-Marie

Published
2024
Full Text
View/download PDF

10. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome

Author

Derosa, Lisa, Iebba, Valerio, Silva, Carolina Alves Costa, Piccinno, Gianmarco, Wu, Guojun, Lordello, Leonardo, Routy, Bertrand, Zhao, Naisi, Thelemaque, Cassandra, Birebent, Roxanne, Marmorino, Federica, Fidelle, Marine, Messaoudene, Meriem, Thomas, Andrew Maltez, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Sibilot, Denis Moro, Goldwasser, François, Scherpereel, Arnaud, Pegliasco, Hervé, Ghiringhelli, François, Bouchard, Nicole, Sow, Cissé, Darik, Ines, Zoppi, Silvia, Ly, Pierre, Reni, Anna, Daillère, Romain, Deutsch, Eric, Lee, Karla A., Bolte, Laura A., Björk, Johannes R., Weersma, Rinse K., Barlesi, Fabrice, Padilha, Lucas, Finzel, Ana, Isaksen, Morten L., Escudier, Bernard, Albiges, Laurence, Planchard, David, André, Fabrice, Cremolini, Chiara, Martinez, Stéphanie, Besse, Benjamin, Zhao, Liping, Segata, Nicola, Wojcik, Jérôme, Kroemer, Guido, and Zitvogel, Laurence

Published
2024
Full Text
View/download PDF

11. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations

Author

Rached, Layal, Laparra, Ariane, Sakkal, Madona, Danlos, François-Xavier, Barlesi, Fabrice, Carbonnel, Franck, De Martin, Eleonora, Ducreux, Michel, Even, Caroline, Le Pavec, Jerome, Michot, Jean-Marie, M. Ribeiro, Joana, Scotte, Florian, Ponce Aix, Santiago, Lambotte, Olivier, Baldini, Capucine, and Champiat, Stéphane

Published
2024
Full Text
View/download PDF

12. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Author

Danlos, François-Xavier, Grajeda-Iglesias, Claudia, Durand, Sylvère, Sauvat, Allan, Roumier, Mathilde, Cantin, Delphine, Colomba, Emeline, Rohmer, Julien, Pommeret, Fanny, Baciarello, Giulia, Willekens, Christophe, Vasse, Marc, Griscelli, Frank, Fahrner, Jean-Eudes, Goubet, Anne-Gaëlle, Dubuisson, Agathe, Derosa, Lisa, Nirmalathasan, Nitharsshini, Bredel, Delphine, Mouraud, Séverine, Pradon, Caroline, Stoclin, Annabelle, Rozenberg, Flore, Duchemin, Jérôme, Jourdi, Georges, Ellouze, Syrine, Levavasseur, Françoise, Albigès, Laurence, Soria, Jean-Charles, Barlesi, Fabrice, Solary, Eric, André, Fabrice, Pène, Frédéric, Ackerman, Félix, Mouthon, Luc, Zitvogel, Laurence, Marabelle, Aurélien, Michot, Jean-Marie, Fontenay, Michaela, and Kroemer, Guido

Published
2024
Full Text
View/download PDF

13. Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

Author

Bayle, Arnaud, Belcaid, Laila, Palmieri, Lola-Jade, Teysonneau, Diego, Cousin, Sophie, Spalato-Ceruso, Mariella, Aldea, Mihaela, Vasseur, Damien, Alame, Melissa, Blouin, Laura, Soubeyran, Isabelle, Nicotra, Claudio, Ngocamus, Maud, Hollebecque, Antoine, Loriot, Yohann, Besse, Benjamin, Lacroix, Ludovic, Rouleau, Etienne, Barlesi, Fabrice, Andre, Fabrice, and Italiano, Antoine

Published
2023
Full Text
View/download PDF

17. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

Author

Vokes, Everett E., Mornex, Francoise, Sezer, Ahmet, Cheng, Ying, Fang, Jian, Baz, David Vicente, Cil, Timucin, Adjei, Alex A., Ahn, Myung-Ju, Barlesi, Fabrice, Felip, Enriqueta, Garon, Edward B., Audhuy, Francois, Ito, Rena, Sato, Masashi, Eggleton, S. Peter, Martin, Claudio Marcelo, Reck, Martin, Robinson, Clifford G., and Paz-Ares, Luis

Published
2024
Full Text
View/download PDF

18. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial

Author

Reck, Martin, Barlesi, Fabrice, Yang, James Chih-Hsin, Westeel, Virginie, Felip, Enriqueta, Özgüroğlu, Mustafa, Dols, Manuel Cobo, Sullivan, Richard, Kowalski, Dariusz M., Andric, Zoran, Lee, Dae Ho, Sezer, Ahmet, Hu, Ping, Wang, XiaoZhe, von Heydebreck, Anja, Jacob, Natalia, Mehr, Keyvan Tadjalli, and Park, Keunchil

Published
2024
Full Text
View/download PDF

19. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Author

Cho, Byoung Chul, Lee, Jong Seok, Wu, Yi-Long, Cicin, Irfan, Dols, Manuel Cobo, Ahn, Myung-Ju, Cuppens, Kristof, Veillon, Rémi, Nadal, Ernest, Dias, Josiane Mourão, Martin, Claudio, Reck, Martin, Garon, Edward B., Felip, Enriqueta, Paz-Ares, Luis, Mornex, Francoise, Vokes, Everett E., Adjei, Alex A., Robinson, Clifford, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Audhuy, Francois, Chaudhary, Surendra, and Barlesi, Fabrice

Published
2023
Full Text
View/download PDF

24. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Author

Hong, David S, Fakih, Marwan G, Strickler, John H, Desai, Jayesh, Durm, Gregory A, Shapiro, Geoffrey I, Falchook, Gerald S, Price, Timothy J, Sacher, Adrian, Denlinger, Crystal S, Bang, Yung-Jue, Dy, Grace K, Krauss, John C, Kuboki, Yasutoshi, Kuo, James C, Coveler, Andrew L, Park, Keunchil, Kim, Tae Won, Barlesi, Fabrice, Munster, Pamela N, Ramalingam, Suresh S, Burns, Timothy F, Meric-Bernstam, Funda, Henary, Haby, Ngang, Jude, Ngarmchamnanrith, Gataree, Kim, June, Houk, Brett E, Canon, Jude, Lipford, J Russell, Friberg, Gregory, Lito, Piro, Govindan, Ramaswamy, and Li, Bob T

Subjects
Clinical Research, Lung, Colo-Rectal Cancer, Lung Cancer, Cancer, Digestive Diseases, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Piperazines, Proto-Oncogene Proteins p21(ras), Pyridines, Pyrimidines, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundNo therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.MethodsWe conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.ResultsA total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma.ConclusionsSotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Published
2020

25. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

Author

Wirth, Lori, Sherman, Eric, Robinson, Bruce, Solomon, Benjamin, Kang, Hyunseok, Lorch, Jochen, Worden, Francis, Brose, Marcia, Patel, Jyoti, Leboulleux, Sophie, Godbert, Yann, Barlesi, Fabrice, Morris, John, Owonikoko, Taofeek, Tan, Daniel, Gautschi, Oliver, Weiss, Jared, de la Fouchardière, Christelle, Burkard, Mark, Laskin, Janessa, Taylor, Matthew, Kroiss, Matthias, Medioni, Jacques, Goldman, Jonathan, Bauer, Todd, Levy, Benjamin, Zhu, Viola, Lakhani, Nehal, Moreno, Victor, Ebata, Kevin, Nguyen, Michele, Heirich, Dana, Zhu, Edward, Huang, Xin, Yang, Luxi, Kherani, Jennifer, Rothenberg, S, Drilon, Alexander, Subbiah, Vivek, Shah, Manisha, and Cabanillas, Maria

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Hypertension, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Progression-Free Survival, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret, Pyrazoles, Pyridines, Thyroid Neoplasms, Transaminases, Treatment Outcome, Young Adult
Abstract

BACKGROUND: RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown. METHODS: We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or cabozantinib treatment, as well as those with previously treated RET fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: In the first 55 consecutively enrolled patients with RET-mutant medullary thyroid cancer who had previously received vandetanib, cabozantinib, or both, the percentage who had a response was 69% (95% confidence interval [CI], 55 to 81), and 1-year progression-free survival was 82% (95% CI, 69 to 90). In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetanib or cabozantinib, the percentage who had a response was 73% (95% CI, 62 to 82), and 1-year progression-free survival was 92% (95% CI, 82 to 97). In 19 patients with previously treated RET fusion-positive thyroid cancer, the percentage who had a response was 79% (95% CI, 54 to 94), and 1-year progression-free survival was 64% (95% CI, 37 to 82). The most common adverse events of grade 3 or higher were hypertension (in 21% of the patients), increased alanine aminotransferase level (in 11%), increased aspartate aminotransferase level (in 9%), hyponatremia (in 8%), and diarrhea (in 6%). Of all 531 patients treated, 12 (2%) discontinued selpercatinib owing to drug-related adverse events. CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Published
2020

26. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Author

Drilon, Alexander, Oxnard, Geoffrey R, Tan, Daniel SW, Loong, Herbert HF, Johnson, Melissa, Gainor, Justin, McCoach, Caroline E, Gautschi, Oliver, Besse, Benjamin, Cho, Byoung C, Peled, Nir, Weiss, Jared, Kim, Yu-Jung, Ohe, Yuichiro, Nishio, Makoto, Park, Keunchil, Patel, Jyoti, Seto, Takashi, Sakamoto, Tomohiro, Rosen, Ezra, Shah, Manisha H, Barlesi, Fabrice, Cassier, Philippe A, Bazhenova, Lyudmila, De Braud, Filippo, Garralda, Elena, Velcheti, Vamsidhar, Satouchi, Miyako, Ohashi, Kadoaki, Pennell, Nathan A, Reckamp, Karen L, Dy, Grace K, Wolf, Jürgen, Solomon, Benjamin, Falchook, Gerald, Ebata, Kevin, Nguyen, Michele, Nair, Binoj, Zhu, Edward Y, Yang, Luxi, Huang, Xin, Olek, Elizabeth, Rothenberg, S Michael, Goto, Koichi, and Subbiah, Vivek

Subjects
Lung Cancer, Clinical Research, Lung, Cancer, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Hypertension, Intention to Treat Analysis, Lung Neoplasms, Male, Middle Aged, Mutation, Progression-Free Survival, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret, Pyrazoles, Pyridines, Transaminases, Treatment Outcome, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundRET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.MethodsWe enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.ResultsIn the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event.ConclusionsSelpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Published
2020

27. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Author

Aldea, Mihaela, Marinello, Arianna, Duruisseaux, Michael, Zrafi, Wael, Conci, Nicole, Massa, Giacomo, Metro, Giulio, Monnet, Isabelle, Gomez Iranzo, Patricia, Tabbo, Fabrizio, Bria, Emilio, Guisier, Florian, Vasseur, Damien, Lindsay, Colin R., Ponce-Aix, Santiago, Cousin, Sophie, Citarella, Fabrizio, Fallet, Vincent, Minatta, Jose Nicolas, Eisert, Anna, de Saint Basile, Hortense, Audigier-Valette, Clarisse, Mezquita, Laura, Calles, Antonio, Mountzios, Giannis, Tagliamento, Marco, Remon Masip, Jordi, Raimbourg, Judith, Terrisse, Safae, Russo, Alessandro, Cortinovis, Diego, Rochigneux, Philippe, Pinato, David James, Cortellini, Alessio, Leonce, Camille, Gazzah, Anas, Ghigna, Maria-Rosa, Ferrara, Roberto, Dall’Olio, Filippo Gustavo, Passiglia, Francesco, Ludovini, Vienna, Barlesi, Fabrice, Felip, Enriqueta, Planchard, David, and Besse, Benjamin

Published
2023
Full Text
View/download PDF

30. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

Author

Mordant, Pierre, MD, PhD, Brosseau, Solenn, Milleron, Bernard, Santelmo, Nicola, Fraboulet-Moreau, Séverine, Besse, Benjamin, Langlais, Alexandra, Gossot, Dominique, Thomas, Pascal-Alexandre, Pujol, Jean-Louis, Ricordel, Charles, Madelaine, Jeannick, Lamy, Régine, Audigier-Valette, Clarisse, Missy, Pascale, Blons, Hélène, Barlesi, Fabrice, and Westeel, Virginie

Published
2023
Full Text
View/download PDF

31. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

Author

Mok, Tony S. K., primary, Yao, Wenxiu, additional, Duruisseaux, Michaël, additional, Doucet, Ludovic, additional, Azkárate Martínez, Aitor, additional, Gregorc, Vanesa, additional, Juan-Vidal, Oscar, additional, Lu, Shun, additional, De Bondt, Charlotte, additional, de Marinis, Filippo, additional, Linardou, Helena, additional, Kim, Young-Chul, additional, Jotte, Robert M., additional, Felip, Enriqueta, additional, Lo Russo, Giuseppe, additional, Reck, Martin, additional, Michenzie, Mary F., additional, Yang, Wenjing, additional, Meade, Julie N., additional, and Barlesi, Fabrice, additional

Published
2024
Full Text
View/download PDF

32. Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Author

Dziadziuszko, Rafal, primary, Barlesi, Fabrice, additional, Kim, Jeong Eun, additional, Gadgeel, Shirish M., additional, Krzakowski, Maciej, additional, Jeong, Jae Ho, additional, Daniele, Gennaro, additional, Chen, David, additional, Hu, Youyou, additional, Wilson, Timothy R., additional, Simmons, Brian P., additional, and Thomas, David Morgan, additional

Published
2024
Full Text
View/download PDF

33. Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

Author

Barlesi, Fabrice, primary, Felip, Enriqueta, additional, Popat, Sanjay, additional, Solomon, Benjamin J., additional, Wolf, Juergen, additional, Li, Bob T., additional, Wu, Yi-Long, additional, Kerr, Keith, additional, Akamatsu, Hiroaki, additional, Camidge, David Ross, additional, Gupta, Ravi G., additional, Meloni, Alison, additional, Dai, Tian, additional, and Borghaei, Hossein, additional

Published
2024
Full Text
View/download PDF

35. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Author

Ou, Sai-Hong Ignatius, Nishio, Makoto, Ahn, Myung-Ju, Mok, Tony, Barlesi, Fabrice, Zhou, Caicun, Felip, Enriqueta, de Marinis, Filippo, Kim, Sang-We, Pérol, Maurice, Liu, Geoffrey, Migliorino, Maria Rita, Kim, Dong-Wan, Novello, Silvia, Bearz, Alessandra, Garrido, Pilar, Mazieres, Julien, Morabito, Alessandro, Lin, Huamao M., Yang, Hui, Niu, Huifeng, Zhang, Pingkuan, and Kim, Edward S.

Published
2022
Full Text
View/download PDF

36. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial

Author

Westeel, Virginie, Foucher, Pascal, Scherpereel, Arnaud, Domas, Jean, Girard, Philippe, Trédaniel, Jean, Wislez, Marie, Dumont, Patrick, Quoix, Elisabeth, Raffy, Olivier, Braun, Denis, Derollez, Marc, Goupil, François, Hermann, Jacques, Devin, Etienne, Barbieux, Hubert, Pichon, Eric, Debieuvre, Didier, Ozenne, Gervais, Muir, Jean-François, Dehette, Stéphanie, Virally, Jérôme, Grivaux, Michel, Lebargy, François, Souquet, Pierre-Jean, Freijat, Faraj Al, Girard, Nicolas, Courau, Emmanuel, Azarian, Reza, Farny, Michel, Duhamel, Jean-Paul, Langlais, Alexandra, Morin, Franck, Milleron, Bernard, Zalcman, Gérard, and Barlesi, Fabrice

Published
2022
Full Text
View/download PDF

38. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Author

Mogenet, Alice, Barlesi, Fabrice, Besse, Benjamin, Michiels, Stefan, Karimi, Maryam, Tran-Dien, Alicia, Girard, Nicolas, Mazieres, Julien, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Kamal, Maud, Gestraud, Pierre, Hamza, Abderaouf, Jacquet, Alexandra, Jimenez, Marta, Yara, Sabrina, Greillier, Laurent, Bertucci, François, Planchard, David, Soria, Jean-Charles, Bieche, Ivan, and Tomasini, Pascale

Published
2022
Full Text
View/download PDF

39. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Author

Cho, Byoung Chul, Abreu, Delvys Rodriguez, Hussein, Maen, Cobo, Manuel, Patel, Anjan J, Secen, Nevena, Lee, Ki Hyeong, Massuti, Bartomeu, Hiret, Sandrine, Yang, James Chih Hsin, Barlesi, Fabrice, Lee, Dae Ho, Ares, Luis Paz, Hsieh, Robert W, Patil, Namrata S, Twomey, Patrick, Yang, Xiaoying, Meng, Raymond, and Johnson, Melissa L

Published
2022
Full Text
View/download PDF

43. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)

Author

Levy, Benjamin, Barlesi, Fabrice, Paz-Ares, Luis, Bennouna, Jaafar, Erman, Mustafa, Felip, Enriqueta, Isla, Dolores, Ryun Kim, Hye, Kim, Sang-We, Madelaine, Jeannick, Molinier, Olivier, Özgüroğlu, Mustafa, Rodríguez Abreu, Delvys, Adeniji, Abidemi, Lorence, Robert M., Voccia, Isabelle, Chisamore, Michael J., and Riess, Jonathan W.

Published
2022
Full Text
View/download PDF

45. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.

Author

Barlesi, Fabrice, Cho, Byoung Chul, Goldberg, Sarah B, Yoh, Kiyotaka, Zimmer Gelatti, Ana Caroline, Mann, Helen, Gopinathan, Aarthi, Bielecka, Zofia Felicja, Newton, Michael, and Aggarwal, Charu

Abstract

Evidence from the Phase III PACIFIC trial established durvalumab, a monoclonal antibody (mAb) targeting PD-L1, following concurrent chemoradiotherapy (cCRT) as a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). There remains an unmet need to improve upon the outcomes achieved with the PACIFIC regimen. Combining durvalumab with other immunotherapies may improve outcomes further. Two such immunotherapies include oleclumab, an mAb targeting CD73, and monalizumab, an mAb targeting NKG2A. Both agents demonstrated antitumor activity in early-phase trials. PACIFIC-9 (NCT05221840) is an international, double-blind, randomized, placebo-controlled, Phase III trial comparing durvalumab plus either oleclumab or monalizumab with durvalumab plus placebo in patients with unresectable, stage III NSCLC and no disease progression following cCRT. Clinical Trial Registration: NCT05221840 (ClinicalTrials.gov) Plain Language Summary Durvalumab is a treatment that helps the body's immune system to identify and attack cancer cells by binding to a protein called PD-L1. Studies show that durvalumab lowers the risk of cancer growing or spreading, and prolongs survival, when administered after chemotherapy and radiation therapy ('chemoradiotherapy') in patients with a type of lung cancer called stage III non-small-cell lung cancer (NSCLC) for whom surgery is not an option. Two antibody treatments have been developed that may help a patient's immune system to identify and attack cancer cells. Oleclumab binds to a protein on cancer cells called CD73, which prevents the production of adenosine, a chemical that obstructs the immune system from attacking the cancer. Monalizumab binds to NKG2A, a protein on immune cells that inhibits their ability to destroy cancer cells. Early studies suggest that combining either of these treatments with durvalumab may be better than durvalumab alone for slowing the growth and spread of cancer in patients with NSCLC. PACIFIC-9 is a study that aims to recruit approximately 999 patients with stage III NSCLC for whom surgery is not an option and who have completed chemoradiotherapy without the cancer growing or spreading. Patients will be randomly assigned in equal numbers to receive up to a year of treatment with durvalumab plus oleclumab, durvalumab plus monalizumab or durvalumab plus placebo. The primary measure of efficacy is the length of time that patients remain alive without the cancer growing or spreading for each combination versus durvalumab plus placebo. Executive summary The PACIFIC regimen Durvalumab is a monoclonal antibody that binds to PD-L1 and overcomes PD-L1 mediated inhibition of T-cell activation, allowing T cells to recognize and kill tumor cells. The Phase III placebo-controlled, PACIFIC trial (NCT02125461) demonstrated significant improvements in progression-free survival (PFS) and overall survival with durvalumab in patients with unresectable, stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed following platinum-based, concurrent chemoradiotherapy (cCRT); the PACIFIC regimen is now a global standard of care in this population. Oleclumab & monalizumab Extracellular adenosine can act as an immunosuppressant within the tumor microenvironment; oleclumab is a monoclonal antibody that binds to and blocks CD73, an enzyme on the surface of tumor cells that drives the production of extracellular adenosine. NKG2A is a receptor on T cells and natural killer (NK) cells that can inhibit T cell and NK cell effector function when it binds to HLA-E; monalizumab is a monoclonal antibody that binds to NKG2A, preventing it from inhibiting NK and T cell function. In the open-label, randomized, Phase II COAST trial (NCT03822351) the combination of durvalumab with oleclumab, and durvalumab with monalizumab, were both associated with encouraging clinical activity compared with durvalumab alone in patients with unresectable, stage III NSCLC and no progression after cCRT; the findings of COAST support further evaluation of these combinations in a Phase III trial. PACIFIC-9 PACIFIC-9 (NCT05221840) is an international, double-blind, randomized, placebo-controlled, Phase III trial comparing the efficacy and safety of durvalumab plus oleclumab and durvalumab plus monalizumab versus durvalumab plus placebo in patients with unresectable, stage III NSCLC. The trial is enrolling men and women aged 18 years or older with histologically or cytologically documented, unresectable, stage III NSCLC according to the TNM system as described in the International Association for the Study of Lung Cancer staging manual (8th edition), whose disease has not progressed following definitive, platinum-based cCRT. The primary end point is PFS, defined as time from randomization until progression per Response Evaluation Criteria in Solid Tumors version 1.1 as assessed by blinded independent central review, or death due to any cause. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Author

Nogami, Naoyuki, Barlesi, Fabrice, Socinski, Mark A., Reck, Martin, Thomas, Christian A., Cappuzzo, Federico, Mok, Tony S.K., Finley, Gene, Aerts, Joachim G., Orlandi, Francisco, Moro-Sibilot, Denis, Jotte, Robert M., Stroyakovskiy, Daniil, Villaruz, Liza C., Rodríguez-Abreu, Delvys, Wan-Teck Lim, Darren, Merritt, David, Coleman, Shelley, Lee, Anthony, Shankar, Geetha, Yu, Wei, Bara, Ilze, and Nishio, Makoto

Published
2022
Full Text
View/download PDF

47. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

Author

Souquet, Pierre-Jean, Audigier-Valette, Clarisse, Molinier, Olivier, Cortot, Alexis, Margery, Jacques, Moreau, Lionel, Gervais, Radj, Barlesi, Fabrice, Pichon, Eric, Zalcman, Gérard, Dumont, Patrick, Girard, Nicolas, Poudenx, Michel, Mazières, Julien, Cadranel, Jacques, Debieuvre, Didier, Dauba, Jérôme, Langlais, Alexandra, Morin, Franck, Moro-Sibilot, Denis, Westeel, Virginie, and Pérol, Maurice

Published
2022
Full Text
View/download PDF

48. Functional status in older patients with cancer

Author

Couderc, Anne-Laure, Suchon, Pierre, Saliba-Serre, Bérengère, Rey, Dominique, Nouguerede, Emilie, Arcani, Robin, Farnault, Laure, Daumas, Aurélie, Courcier, Anais, Duffaud, Florence, Salas, Sébastien, Barlesi, Fabrice, Greillier, Laurent, Costello, Régis, Venton, Geoffroy, and Villani, Patrick

Published
2022
Full Text
View/download PDF

49. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Author

Planchard, David, Besse, Benjamin, Groen, Harry J.M., Hashemi, Sayed M.S., Mazieres, Julien, Kim, Tae Min, Quoix, Elisabeth, Souquet, Pierre-Jean, Barlesi, Fabrice, Baik, Christina, Villaruz, Liza C., Kelly, Ronan J., Zhang, Shirong, Tan, Monique, Gasal, Eduard, Santarpia, Libero, and Johnson, Bruce E.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results